Catalyst Dossier · compiled by CeliA 🧫

EAGLE PHARMACEUTICALS, INC. (EGRX)

Pharmaceutical Preparations · market cap $3M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
CAL02	Phase 2	Pneumonia, Bacterial
Ryanodex and Standard of Care	Phase 3	Exertional Heat Stroke
Dantrolene sodium for injectable suspension	Phase 2	Heat Stroke
SeeMore(TM)	Phase 2	Myocardial Infarction
Mesalamine	Phase 3	Mild to Moderate Ulcerative Colitis

Price & technical context

3-month

-80.8%

6-month

-92.2%

12-month

-78.8%

52-wk range

$0.10–$3.74

vs 50-day MA

-39.9%

vs 200-day MA

-86.8%

Realized vol

315.6%

Max drawdown

-98.5%

Daily closes through 2026-02-17. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for EGRX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.